Sen. Dan Kotowski

Filed: 4/11/2011

 

 


 

 


 
09700SB0670sam001LRB097 04433 CEL 54208 a

1
AMENDMENT TO SENATE BILL 670

2    AMENDMENT NO. ______. Amend Senate Bill 670 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Pharmacy Practice Act is amended by
5changing Section 26 as follows:
 
6    (225 ILCS 85/26)
7    (Section scheduled to be repealed on January 1, 2018)
8    Sec. 26. Anti-epileptic drug product selection prohibited.
9    (a) The General Assembly finds that this Section is
10necessary for the immediate preservation of the public peace,
11health, and safety.
12    (b) In this Section:
13    "Anti-epileptic drug" means (i) any drug prescribed for the
14treatment of epilepsy or (ii) a drug used to treat or prevent
15seizures.
16    "Epilepsy" means a neurological condition characterized by

 

 

09700SB0670sam001- 2 -LRB097 04433 CEL 54208 a

1recurrent seizures.
2    "Seizure" means a brief disturbance in the electrical
3activity of the brain.
4    (c) When the prescribing physician has indicated on the
5original prescription "may not substitute", a pharmacist may
6not interchange an anti-epileptic drug or formulation of an
7anti-epileptic drug for the treatment of epilepsy without
8notification and the documented consent of the prescribing
9physician and the patient or the patient's parent, legal
10guardian, or spouse. This Section does not apply to medication
11orders issued for anti-epileptic drugs for any in-patient care
12in a licensed hospital.
13    (d) If a pharmacist substitutes any generic prescription in
14place of a brand-name anti-epileptic drug, then the pharmacist
15shall provide written notice to the patient no later than the
16time the prescription is dispensed.
17(Source: P.A. 94-936, eff. 6-26-06; 95-689, eff. 10-29-07.)".